RNXT - שולי רווח נקי ממכירות RenovoRx, Inc.

RenovoRx Inc - לוגו גרפי של המנפיק RNXT

RenovoRx, Inc. (RNXT) is developing the RenovoCath platform for local chemotherapy, supported by FDA orphan drug status. The realization margin ratio helps track financial stability, with the value holding at -469.00. The company attracts bioengineers through its innovative approach and stock options. Revenues are based on the supply of targeted tumor delivery systems to specialized hospitals and surgical centers.

רווחיות מכירות נקייה RenovoRx, Inc. (RNXT): לתקופה 04.07.2022 - 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור RenovoRx Corporation (RNXT)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח מקיף של החברה:RenovoRx, Inc.
מוצרים מוגמרים של RenovoRx Corp

Sales margin measures the proportion of net profit to revenue, reflecting the efficiency of cost management relative to incoming cash flows. This indicator determines the business's margin of safety and its ability to survive a decline in demand. For RenovoRx, Inc. (RNXT), which is in the clinical trial stage without stable revenue, this metric highlights a critical dependence on external capital. The month-over-month sales margin trend visualizes the cash burn rate prior to product commercialization.